Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:02:04 2024-06-21 pm EDT 5-day change 1st Jan Change
27.74 USD 0.00% Intraday chart for Pfizer, Inc. +0.76% -3.65%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sarepta surges as investors cheer expanded use of gene therapy RE
Sarepta surges as investors cheer expanded use of gene therapy RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... Our Logo
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday MT
Pfizer Sued by Kansas Over Covid-19 Vaccine MT
Certain Ordinary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI
Certain American Depositary Shares of Haleon plc are subject to a Lock-Up Agreement Ending on 18-JUN-2024. CI
US FDA approves Merck's pneumococcal vaccine for adults RE
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit RE
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug RE
FDA asks COVID vaccine makers to target KP.2 strain with updated shots RE
Pfizer: improved overall survival in myeloma CF
Pfizer's Phase 2 MagnetisMM-3 Study of ELREXFIO Shows Median Overall Survival of Over 2 Years MT
Pfizer Inc. Announces Detailed Overall Survival Results from the Phase 2 MagnetisMM-3 Study of ELREXFIO CI
Health Care Flat on Mixed Drug Developments - Health Care Roundup DJ
Global markets live: Shell, Broadcom, Apple, Sony, Apple... Our Logo
Pfizer : share price down, Duchenne clinical trial failure CF
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Only one rate cut this year? Our Logo
Pfizer: presents results of treatment for DMD CF
Pfizer Prospective Treatment for Duchenne Muscular Dystrophy Fails to Meet Goals MT
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints DJ
Pfizer's gene therapy for a muscle-wasting disorder misses main goal of late-stage study RE
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says MT
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
27.74 USD
Average target price
31.92 USD
Spread / Average Target
+15.05%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer Looks for $1.5 Billion in Savings by 2027, Expects One-Time Cost Reduction Charge of $1.7 Billion